Who has been buying Qurient stock?

4 distinct insiders have filed 16 disclosed insider purchases in Qurient (115180), most recently on 2026-04-30. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.

How many insider filings does Qurient have?

Qurient has 16 buy-side and 2 sell-side disclosures on record, covering ₩1.1B ($748K) in total reported value, spanning 2024-05-18 to 2026-04-30.

Do insider buys in Korean stocks predict returns?

Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Qurient 115180

Company

큐리언트Qurient

Insiders

Buys

Total Value

₩1.1B ($748K)

Avg Return

+492.93%

Last Filing

2026-04-30

Qurient (115180) has 16 disclosed insider purchases and 2 disclosed disposals on record, filed by 4 distinct insiders. Together those filings cover ₩1.1B ($748K) in reported transaction value. The earliest filing StockDrifts holds for Qurient is dated 2024-05-18; the most recent is 2026-04-30. Across these filings the average return since disclosure is +492.93%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

Date	Type	Source	Insider	Position	Shares	Price at filing	Return	Value
2026-07-29	BUY	주식매수선택권	유창연 Yoo Chang-yeon	vice president	10.0K	₩15,140	+10.0%	₩61M ($42K)
2026-04-30	BUY	주식매수선택권	유창연 Yoo Chang-yeon	vice president	12.0K	₩37,300	+0.0%	₩448M ($311K)
2026-04-29	BUY	주식매수선택권	임현진 Hyunjin Lim	Managing Director	17.0K	₩39,300	-5.1%	₩668M ($464K)
2026-04-29	BUY	주식매수선택권	허태석 Heo Tae-seok	moving	17.0K	₩39,300	-5.1%	₩668M ($464K)
2026-04-29	BUY	주식매수선택권	김정준 Jeongjun Kim	Managing Director	11.6K	₩39,300	-5.1%	₩454M ($316K)
2026-04-02	BUY	Market Buy	김성우 Seongwoo Kim	thanks	1.0K	₩36,150	+9.5%	₩36M ($25K)
2026-04-01	BUY	Market Buy	김성우 Seongwoo Kim	thanks	1.0K	₩40,250	-1.6%	₩40M ($28K)
2026-03-26	SELL	Market Sell	김재승 Jaeseung Kim	vice president	-2.0K	₩41,000	+1.2%	₩81M ($56K)
2026-03-25	BUY	주식매수선택권	김재승 Jaeseung Kim	vice president	6.0K	₩39,600	+2.3%	₩238M ($165K)
2026-03-25	BUY	주식매수선택권	남기연 Nam Ki-yeon	CEO	20.0K	₩39,600	+2.3%	₩792M ($550K)
2026-03-25	SELL	Market Sell	김재승 Jaeseung Kim	vice president	-2.0K	₩39,600	-2.3%	₩80M ($56K)
2026-02-23	BUY	콜옵션권리행사에따른주식취득	동구바이오제약 Donggu Bio Pharmaceutical	-	488.2K	₩32,750	+2.9%	₩16.0B ($11.1M)
2026-02-23	BUY	콜옵션권리행사에따른주식취득	조용준 Cho Yongjun	Other non-executive directors (Chairman of the Board of Directors)	104.0K	₩32,750	+2.9%	₩3.4B ($2.4M)
2026-02-23	BUY	콜옵션권리행사에따른주식취득	이병걸 Lee Byung-geol	Other non-executive directors	15.0K	₩32,750	+2.9%	₩491M ($341K)
2026-01-29	BUY	주식매수선택권	김정준 Jeongjun Kim	moving	4.0K	₩35,700	-5.6%	₩143M ($99K)
2026-01-29	BUY	주식매수선택권	임현진 Hyunjin Lim	Managing Director	5.0K	₩35,700	-5.6%	₩179M ($124K)
2025-12-03	BUY	주식매수선택권	김정준 Jeongjun Kim	moving	6.0K	₩32,100	+5.0%	₩193M ($134K)
2025-11-18	BUY	주식매수선택권	이승주 Seungju Lee	vice president	28.0K	₩27,250	+23.7%	₩763M ($530K)
2025-11-06	BUY	주식매수선택권	허태석 Heo Tae-seok	moving	10.0K	₩20,650	+63.2%	₩207M ($143K)
2025-11-06	BUY	주식매수선택권	임현진 Hyunjin Lim	Managing Director	4.0K	₩20,650	+63.2%	₩83M ($57K)
2025-09-26	BUY	주식매수선택권	임현진 Hyunjin Lim	Managing Director	6.0K	₩15,840	+112.8%	₩95M ($66K)
2025-09-24	BUY	주식매수선택권	임현진 Hyunjin Lim	Managing Director	2.0K	₩15,000	+124.7%	₩30M ($21K)
2025-07-15	SELL	시간외매매	임현진 Hyunjin Lim	Managing Director	-7.0K	₩11,120	-203.1%	₩78M ($54K)
2025-07-15	BUY	시간외매매	임현진 Hyunjin Lim	Managing Director	7.0K	₩11,120	+203.1%	₩78M ($54K)
2025-04-21	SELL	증여	김재승 Jaeseung Kim	vice president	-5.0K	₩10,240	-229.1%	₩51M ($36K)
2025-04-21	SELL	증여	김재승 Jaeseung Kim	vice president	-5.0K	₩10,240	-229.1%	₩51M ($36K)
2025-04-11	BUY	제3자배정유상증자	동구바이오제약 Donggu Bio Pharmaceutical	-	1.3M	₩8,300	+306.0%	₩11.2B ($7.7M)
2025-04-02	SELL	증여	김현정 Hyunjeong Kim	moving	-3.0K	₩8,130	-314.5%	₩24M ($17K)
2025-04-02	SELL	증여	김현정 Hyunjeong Kim	moving	-3.2K	₩8,130	-314.5%	₩26M ($18K)
2025-04-02	SELL	증여	김현정 Hyunjeong Kim	moving	-3.1K	₩8,130	-314.5%	₩25M ($18K)
2025-03-20	BUY	Market Buy	이병걸 Lee Byung-geol	Other non-executive directors	8.4K	₩7,500	+349.3%	₩63M ($44K)
2024-11-29	BUY	Market Buy	동구바이오제약 Donggu Bio Pharmaceutical	-	4.0K	₩4,855	+594.1%	₩20M ($14K)
2024-11-28	BUY	Market Buy	동구바이오제약 Donggu Bio Pharmaceutical	-	28.1K	₩4,860	+593.4%	₩136M ($95K)
2024-11-27	BUY	Market Buy	동구바이오제약 Donggu Bio Pharmaceutical	-	3.3K	₩4,615	+630.2%	₩15M ($11K)
2024-11-26	BUY	Market Buy	동구바이오제약 Donggu Bio Pharmaceutical	-	18.9K	₩4,485	+651.4%	₩85M ($59K)
2024-11-25	BUY	Market Buy	동구바이오제약 Donggu Bio Pharmaceutical	-	10.4K	₩4,485	+651.4%	₩47M ($32K)
2024-11-22	BUY	Market Buy	동구바이오제약 Donggu Bio Pharmaceutical	-	4.6K	₩4,420	+662.4%	₩21M ($14K)
2024-11-22	BUY	CB인수	동구바이오제약 Donggu Bio Pharmaceutical	-	1.3M	₩4,420	+662.4%	₩5.8B ($4.0M)
2024-11-20	BUY	Market Buy	동구바이오제약 Donggu Bio Pharmaceutical	-	15.8K	₩4,430	+660.7%	₩70M ($49K)
2024-11-19	BUY	Market Buy	동구바이오제약 Donggu Bio Pharmaceutical	-	2.7K	₩4,375	+670.3%	₩12M ($8K)
2024-11-18	BUY	Market Buy	동구바이오제약 Donggu Bio Pharmaceutical	-	6.4K	₩4,285	+686.5%	₩27M ($19K)
2024-11-15	BUY	Market Buy	동구바이오제약 Donggu Bio Pharmaceutical	-	37.5K	₩4,300	+683.7%	₩161M ($112K)
2024-11-14	BUY	Market Buy	동구바이오제약 Donggu Bio Pharmaceutical	-	9.1K	₩4,200	+702.4%	₩38M ($26K)
2024-11-13	BUY	Market Buy	동구바이오제약 Donggu Bio Pharmaceutical	-	7.2K	₩4,315	+681.0%	₩31M ($22K)
2024-11-12	BUY	Market Buy	동구바이오제약 Donggu Bio Pharmaceutical	-	25.3K	₩4,500	+648.9%	₩114M ($79K)
2024-09-26	BUY	신규보고	이병걸 Lee Byung-geol	Other non-executive directors	2.8K	₩4,280	+687.4%	₩12M ($8K)
2024-05-18	BUY	제3자배정유상증자	동구바이오제약 Donggu Bio Pharmaceutical	-	2.6M	₩4,195	+703.3%	₩10.7B ($7.5M)

Frequently asked questions

Who has been buying Qurient stock?: 4 distinct insiders have filed 16 disclosed insider purchases in Qurient (115180), most recently on 2026-04-30. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Qurient have?: Qurient has 16 buy-side and 2 sell-side disclosures on record, covering ₩1.1B ($748K) in total reported value, spanning 2024-05-18 to 2026-04-30.
Do insider buys in Korean stocks predict returns?: Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

More on this data

Every trade listed above comes from an official regulatory disclosure. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.